During menopause, the levels of the sex hormone estrogen drop leading to a group of symptoms — confusion, forgetfulness, difficulty focusing on a task…
Last April, the Centers for Medicare and Medicaid Services (CMS) decided to limit the coverage of the controversial Alzheimer’s drug Aduhelm and similar drugs…
A human being has as many as 25,000 different genes in their DNA. It’s wild to think that just one tiny little mutation can…
Mounting evidence shows that viruses lead to brain degeneration. So, scientists are trying a new approach to treating Alzheimer’s: antivirals. Infections — from herpes…
The family of Bruce Willis released a statement revealing that the actor has been diagnosed with frontotemporal dementia (FTD). Willis stepped away from acting…
Scientists still don’t know what causes Alzheimer’s, but they do have one, long-standing theory: the amyloid hypothesis. Some say it’s on the brink of…
Christiana Egi is the owner of the Alexis Lodge — a home to more than 20 people living with dementia. But why stop there?…
In a Scottish study, the brains of beached dolphins, whales, and porpoises showed the same biomarkers as the brain of a human with Alzheimer’s….
Eisai and Biogen’s new anti-amyloid drug Leqembi was recently approved through the FDA’s accelerated pathway. Now, it’s on the market with a price tag…
People diagnosed with cancer are less likely to develop dementia. Scientists probe the strange relationship between these diseases seeking clues for dementia prevention. Dementia…
Could getting serious about exercise really have a substantial impact on cognition as we age? Determining exactly how often someone needs to work out…
Memory loss, confusion, cognitive impairment, and brain inflammation. Those aren’t just the signs and symptoms of Alzheimer’s disease and dementia. A year after a…
Update: As of July 6, 2023, the drug has full, traditional FDA approval. Today, the Food and Drug Administration approved Leqembi (generic name lecanemab), a…
After a successful trial, an FDA decision on Alzheimer’s drug candidate lecanemab is expected as soon as this week. Experts say we may be…
Lecanemab, Eisai and Biogen’s experimental anti-amyloid Alzheimer’s drug, which recently wrapped its Phase 3 clinical trials, continues to make the news. Some of these…